Bristol-Myers Squibb Bets Big on Next-Generation Cancer Treatment

Pharmaceutical giant Bristol-Myers Squibb is making a substantial $1.5 billion strategic move to acquire biotechnology firm Orbital Therapeutics, signaling a major commitment to advancing its position in innovative cancer therapies. This significant investment aims to secure the company’s future pipeline, though initial investor reception has been marked by caution.

The acquisition represents a strategic imperative for Bristol-Myers Squibb as it confronts impending revenue challenges. The company faces substantial patent expirations for key revenue-generating drugs including Eliquis and Revlimid in the coming years. This transaction forms part of a broader strategy to diversify its therapeutic portfolio and offset potential revenue declines.

This move follows the company’s earlier strategic action in March 2025, when it secured full control over the... Read more...